Evidence map›Paper›PMID 41311760›Full record

ArticleCureus2025

A Rare Case of Inflammatory Luminal B (HER2-Positive) Breast Cancer Misdiagnosed in a 30-Year-Old Woman: A Case Report.

Jenny A Zablah, Jorge J Calderon, Angeli N Burgos, Jose A Gasca, Kevin A Montoya, Leiby Orellana Banegas, Marlene Gracia

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jenny A ZablahGeneral Practice, Universidad Tecnológica Centroamericana, Tegucigalpa, HND.
Jorge J CalderonInternal Medicine, Universidad Nacional Autonoma de Honduras, San Pedro Sula, HND.
Angeli N BurgosEmergency Department, Hospital Escuela Universitario, Tegucigalpa, HND.
Jose A GascaMedicine, Universidad Santiago de Cali, Cali, COL.
Kevin A MontoyaHealth Sciences, Universidad Nacional Autonoma de Honduras, San Pedro Sula, HND.
Leiby Orellana BanegasGeneral Practice, Universidad Catolica de Honduras, San Pedro Sula, HND.
Marlene GraciaMedicine, Universidad Autonoma de Nuevo Leon, Monterrey, MEX.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 30-year-old woman presented with a six-month history of a rapidly enlarging, painful mass in the left breast, accompanied by erythema and intermittent fever. Initial imaging suggested a benign lesion, with differential diagnoses including granulomatous mastitis and phyllodes tumor. She was treated empirically with antibiotics and corticosteroids, but her symptoms worsened. Follow-up imaging revealed further mass enlargement and persistent inflammatory changes. A core needle biopsy confirmed human epidermal growth factor receptor 2 (HER2)-positive, lymphocyte-poor invasive ductal carcinoma, Nottingham Grade III, with a high Ki-67 index and extensive necrosis. Staging studies showed no distant metastases. The patient is recommended to undergo neoadjuvant chemotherapy with HER2 targeted therapy, with plans for radical mastectomy and axillary lymph node dissection. This case underscores the diagnostic challenge of distinguishing inflammatory breast conditions. Inflammatory breast symptoms unresponsive to conservative treatment should prompt early biopsy and multidisciplinary evaluation to avoid delays in diagnosis, especially in young women presenting with atypical features.

Indexed as

breast imagingdifferential diagnosisgranulomatous mastitisher2-positiveinflammatory breast cancerinvasive ductal carcinomamisdiagnosisneoadjuvant therapy

Identifiers

PMID41311760
PMCPMC12657040

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.